Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
- PMID: 21935327
- PMCID: PMC3169974
- DOI: 10.2147/CEOR.S16061
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
Abstract
Purpose: To assess change in hospitalization and cost of care from 6 months pre- to 6 months post-initiation on any depot antipsychotic among schizophrenia patients.
Patients and methods: Using a large United States commercial claims and encounters database, patients younger than 65 years diagnosed with schizophrenia were identified. Patients initiated on a depot antipsychotic were studied in a mirror-image design to assess change in hospitalization rates, mean duration hospitalized, and hospitalization cost. McNemar's test and paired t-tests compared the proportions of patients hospitalized and the mean duration. Paired t-test and bootstrapping methods compared costs.
Results: In these patients (n = 147), psychiatric hospitalizations declined from 49.7% pre-initiation to 22.4% post-initiation (P < 0.001), and the mean hospitalized duration for psychiatric purposes numerically declined from 7.3 to 4.7 days (P = 0.05). Total health care costs declined from $11,111 to $7884 (P < 0.05) driven by reduction in costs for psychiatric hospitalizations from $5384 to $2538 (P < 0.05).
Conclusion: Initiation of depot antipsychotic therapy appeared to be associated with a decline in hospitalization rates and costs. Current findings suggest that treatment with depot antipsychotics may be a cost-effective option for a subgroup of patients with schizophrenia who are at high risk of nonadherence with their oral antipsychotic medication regimen.
Keywords: claims database; depot antipsychotics; mirror-image; treatment outcomes.
References
-
- Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68:1163–1171. - PubMed
-
- Weiden P, Zygmunt A. Medication noncompliance in schizophrenia. Part I. Assessment. J Pract Psychiatry Behav Health. 1997;3:106–110.
-
- Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49:196–201. - PubMed
LinkOut - more resources
Full Text Sources